“The FDA is on notice though, and therein is the benefit of initiation of the EMA's regulatory submission announcement, on a timeline.”
This may be the answer to a posters previous question as to the timing of this PR. With Rett Syndrome in the bag in large part due to the great results of the first two trials perhaps Anavex is starting to leverage its diversity of trial geographical sites with the various government entities.
News 
Market Data 
Discover 
